Wishahi Mohamed, Khalil Heba, Kamel Noura
J Egypt Soc Parasitol. 2017 Apr;47(1):101-105.
This study evaluated the association between expression of Twist2 monogenic, with pathological features and clinical outcomes of squamous cell carcinoma of the urinary bladder (SCCUB) following radical cystectomy (RC). Immunohistochemical staining Twist2 was performed on tissue archival samples comprising normal urothelium from ten controls, cystectomy specimens from 87, patients with T2 NO MO and T3-4a NO MO of bladder squamous cell carcinoma (SCC).all patients with T2-4 SCC undergone radical cystectomy and urinary diversion, follow up was for 5-10 years to assess overall survival (OS) and disease free survival (DFS). Specimens from 10 muscle-invasive urothelial carcinoma patients were reassessed for Twist2 expression to represent over- expression of Twist2. All ten controls had normal status of biomarkers which was negative. Negative or, low, and medium expression of Twist2 was noted in SCC of the urinary bladder of local pathological status with no lymph node metastasis or distant metastasis, clinicopathologic characteristics of the cohort were pT2NO MO (n=659 and pT3-4a NO MO (n= 22). Twist2 negative expression was in 36 case, weak expression (n=33), medium expression (n=16), there were no strong expression. Twist2 low-regulation with combination of tomor stage in SCC of the urinary bladder werel independently associated with overall survival and free disease survival, 7.7 and 5 years survival in pT2 NO MO(n=65) were 89% and 13% respectively, 7.7 and 5 years survival in pT3-4a NO MO(n=22) were 72.7% and 22.7% respectively.
本研究评估了Twist2单基因表达与根治性膀胱切除术后膀胱鳞状细胞癌(SCCUB)的病理特征及临床结局之间的关联。对组织存档样本进行Twist2免疫组化染色,这些样本包括来自10名对照者的正常尿路上皮、87例膀胱鳞状细胞癌(SCC)T2 NO MO和T3 - 4a NO MO患者的膀胱切除标本。所有T2 - 4期SCC患者均接受了根治性膀胱切除术及尿流改道,随访5 - 10年以评估总生存期(OS)和无病生存期(DFS)。对10例肌层浸润性尿路上皮癌患者的标本重新评估Twist2表达以代表Twist2的过表达。所有10名对照者的生物标志物状态均正常且为阴性。在无淋巴结转移或远处转移的膀胱SCC局部病理状态中,观察到Twist2呈阴性、低表达及中等表达,该队列的临床病理特征为pT2NO MO(n = 65)和pT3 - 至4a NO MO(n = 22)。Twist2阴性表达36例,弱表达(n = 33),中等表达(n = 16),无强表达。膀胱SCC中Twist2低表达与肿瘤分期相结合与总生存期和无病生存期独立相关,pT2 NO MO(n = 65)患者7年和5年生存率分别为89%和13%,pT3 - 4a NO MO(n = 22)患者7年和5年生存率分别为72.7%和22.7%。